NCT00896675

Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Proteomic Prediction of Clinical Benefit in HNSCC

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 352 (actual)
• Sponsor: Vanderbilt-Ingram Cancer Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.

Detailed description

OBJECTIVES: * To identify head and neck squamous cell cancer patients who will benefit from treatment with the EGFR inhibitors (i.e., erlotinib hydrochloride, gefitinib, and cetuximab) and VEGF inhibitor (i.e., bevacizumab), based on predictive proteomic profiles in patient blood samples. OUTLINE: This is a multicenter study. Blood samples are analyzed for proteomic profile to determine good and bad prognoses in patients treated with or without EGFR inhibitors and/or a VEGF inhibitor.

Conditions

• Head and Neck Cancer

Interventions

Type	Name	Description
OTHER	proteomic profiles	blood samples analysis
OTHER	proteomic profiles	blood samples analysis

Timeline

• Start date: 2007-06-01
• Primary completion: 2008-12-01
• Completion: 2009-12-01
• First posted: 2009-05-12
• Last updated: 2013-04-02

Locations

3 sites across 1 country: United States